NCT03473756
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03473756 |
| Title | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) |
| Acronym | FORT-2 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | Bayer |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | ITA | FRA | ESP | DEU | AUT |
CKB BOOST